| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 20 | 480 | 2,540 | 2,260 | 2,140 |
| Sales Growth | -95.83% | -81.10% | +12.39% | +5.61% | -15.08% |
| Net Income | -540 | -1,040 | -710 | -620 | -620 |
| Net Income Growth | +48.08% | -46.48% | -14.52% | unch | -77.14% |
Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
BioNexus Gene Lab Corp. is an emerging company in the business of selling chemical raw materials principally in the Southeast Asia region and the development of biopsy tests for early diagnosis and personalized health management. BioNexus Gene Lab Corp. is based in KUALA LUMPUR, Malaysia.
Fiscal Year End Date: 12/31